Abstract
Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer, tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous chromosomal abnormality, and the side effects of current chemotherapies are some of challenges that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC) opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel treatment based on iPSC technology.
Keywords: Leukemia, iPSC, treatment, reprogrammed NK cells, miRNAs, gene therapy, iHSC, malignancy modeling.
Current Stem Cell Research & Therapy
Title:A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future
Volume: 13 Issue: 8
Author(s): Amirhosein Maali, Amir Atashi, Sasan Ghaffari, Reza Kouchaki, Fereshteh Abdolmaleki and Mehdi Azad*
Affiliation:
- Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin,Iran
Keywords: Leukemia, iPSC, treatment, reprogrammed NK cells, miRNAs, gene therapy, iHSC, malignancy modeling.
Abstract: Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer, tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous chromosomal abnormality, and the side effects of current chemotherapies are some of challenges that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC) opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel treatment based on iPSC technology.
Export Options
About this article
Cite this article as:
Maali Amirhosein , Atashi Amir , Ghaffari Sasan , Kouchaki Reza , Abdolmaleki Fereshteh and Azad Mehdi *, A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future, Current Stem Cell Research & Therapy 2018; 13 (8) . https://dx.doi.org/10.2174/1574888X13666180731155038
DOI https://dx.doi.org/10.2174/1574888X13666180731155038 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selective Histone Deacetylase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions
Current Diabetes Reviews Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Antitumoral Alkylphospholipids Alter Cell Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Enhancement of Contractile Force Generation of Artificial Skeletal Muscle Tissues by Mild and Transient Heat Treatment
Current Pharmaceutical Biotechnology The Potential use of Dendritic Cell-based Immunotherapy for Treatment of Pancreatic Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Observations on the Use of the Avian Chorioallantoic Membrane (CAM) Model in Investigations into Angiogenesis
Current Drug Targets - Cardiovascular & Hematological Disorders Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review
Current Drug Targets Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology In Silico Discovery and Virtual Screening of Multi-Target Inhibitors for Proteins in Mycobacterium tuberculosis
Combinatorial Chemistry & High Throughput Screening Interferon alpha for Treatment of Chronic Myeloid Leukemia
Current Drug Targets Cell Arrest and Apoptosis Induced by the Next Generation of Vanadium Based Drugs: Action Mechanism to Structure Relation and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Current Genomics